Survival from metastatic gastrointestinal stromal tumors in the era of imatinib

ASCO SIGN IN

Username:

Create an account

Why Be A Member?

Password:

Remember me

Forgot your username or password?

The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

ASCO Home

Meetings

Abstracts

2008 Gastrointestinal Cancers Symposium

Survival from metastatic gastrointestinal stromal tumors in the era of imatinib

Sub-category:

Multidisciplinary Treatment

Category:

Esophagus and Stomach

Meeting:

2008 Gastrointestinal Cancers Symposium

Abstract No:

Author(s):

A. Artinyan, J. Kim, P. Soriano, J. D. Ellenhorn

Abstract:

Introduction: Metastatic gastrointestinal stromal tumors (GIST) are aggressive malignancies with poor clinical outcomes. In 2002, the Food and Drug Administration approved imatinib for the treatment of metastatic and unresectable GIST following the demonstration of significant partial response. Imatinib's effect on overall survival for metastatic GIST, however, has yet to be established. Methods: The Surveillance, Epidemiology, and End Results (SEER) registry was queried for all patients diagnosed with GIST between 1995 and 2004. Patients were categorized by year of diagnosis into two groups, 1995-2000 and 2001-2004, in order to evaluate the treatment effect of imatinib. Kaplan-Meier curves were constructed to assess differences in survival over time. Multivariate Cox-regression analysis was performed to determine trends in survival adjusted for other clinical and demographic factors. Results: Of 2,467 patients with GIST identified between 1995 and 2004, 552 had metastatic disease. The overall median survival for patients with metastatic GIST was 23 months. Examination of survival in the 1995-2001 and 2001-2004 time groups revealed a significant increase in median survival from 12 to 33 months, respectively (p<0.001); 3- year overall survival increased from 24% to 48%, respectively (p<0.001). On multivariate analysis adjusting for age and surgical resection, diagnosis in the 2001-2004 period was a significant independent predictor for improved survival in patients with metastatic GIST (HR 0.45, 95% CI 0.35-0.58, p<0.001). Conclusions: Clinical outcomes for patients with metastatic GIST have improved significantly in the era of imatinib. Although the majority of patients still die of metastatic disease, imatinib has dramatically improved survival.

Abstract Disclosures

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy and are designated with a caret symbol (^) here and in the print version.

Associated Presentation(s):

1. Survival from metastatic gastrointestinal stromal tumors in the era of imatinib

Meeting: 2008 Gastrointestinal Cancers Symposium
Presenter: Avo Artinyan, MD, MS
Session: General Poster Session A (Poster Presentation)

Other Abstracts in this Sub-Category:

		1. Correlation of imatinib plasma levels with clinical benefit in patients (Pts) with unresectable/metastatic gastrointestinal stromal tumors (GIST) Meeting: 2008 Gastrointestinal Cancers Symposium Abstract No: 3 First Author: G. D. Demetri Category: Esophagus and Stomach - Multidisciplinary Treatment
		2. Post-treatment 18-FDG PET scans in esophageal cancer patients receiving combination chemoradiation: Too much information? Meeting: 2008 Gastrointestinal Cancers Symposium Abstract No: 4 First Author: A. A. Konski Category: Esophagus and Stomach - Multidisciplinary Treatment
		3. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). Meeting: 2008 Gastrointestinal Cancers Symposium Abstract No: 5 First Author: H. Imamura Category: Esophagus and Stomach - Multidisciplinary Treatment
		More...

Abstracts by A. Artinyan:

		1. Evaluation of the potential association of preoperative chemotherapy with steatohepatitis in surgical patients with hepatic colorectal metastases. Meeting: 2009 ASCO Annual Meeting Abstract No: e15009 First Author: A. Artinyan Category: Gastrointestinal (Colorectal) Cancer - Colorectal Cancer (including liver metastases)
		2. Relative outcomes for Asian-Americans with gastric adenocarcinoma. Meeting: 2009 Gastrointestinal Cancers Symposium Abstract No: 3 First Author: B. A. Mailey Category: Esophagus and Stomach - Multidisciplinary Treatment
		3. Stark racial disparities in outcomes for colorectal cancer in Los Angeles County. Meeting: 2009 Gastrointestinal Cancers Symposium Abstract No: 324 First Author: A. Artinyan Category: Colon and Rectum - Prevention, diagnosis, and screening
		More...

Presentations by A. Artinyan:

		1. Stark racial disparities in outcomes for colorectal cancer in Los Angeles County. Meeting: 2009 Gastrointestinal Cancers Symposium Presenter: Avo Artinyan, MD, MS Session: General Poster Session F (Poster Presentation)
		2. Ethnic differences in outcome from resected gastric adenocarcinoma in the United States: Improved survival in Asian Americans. Meeting: 2008 ASCO Annual Meeting Presenter: Avo Artinyan, MD, MS Session: Gastrointestinal (Noncolorectal) Cancer (General Poster Session)
		3. Socioeconomic disparities in patients with metastatic gastrointestinal stromal tumors: Imatinib and the shift toward equality Meeting: 2008 Gastrointestinal Cancers Symposium Presenter: Avo Artinyan, MD, MS Session: General Poster Session B (Poster Presentation)
		More...

Educational Book Manuscripts by A. Artinyan:

No items found.